FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Center | Date | Time | Location |
---|---|---|---|
CDER | August 27, 2004 | 8 a.m. - 5:30 p.m. | Food and Drug
Administration |
Agenda:
The committee will discuss new drug application (NDA) 21–756, pegaptanib
sodium injection (proposed tradename, Macugen) by Eyetech Pharmaceuticals, Inc.,
indicated for the treatment of exudative (wet) age-related macular degeneration.
Background material and meeting information will become available no later than one business day before the meeting (Simply select the appropriate committee link).
Procedure:
Interested persons may present data, information, or views, orally or in writing,
on issues pending before the committee. Written submissions may be made to the
contact person by August 13, 2004. Oral presentations from the public will be
scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation
may be limited. Those desiring to make formal oral presentations should notify
the contact person before August 13, 2004, and submit a brief statement of the
general nature of the evidence or arguments they wish to present, the names
and addresses of proposed participants, and an indication of the approximate
time requested to make their presentation. Persons attending FDA's advisory
committee meetings are advised that the agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the public at its advisory committee meetings
and will make every effort to accommodate persons with physical disabilities
or special needs. If you require special accommodations due to a disability,
please contact Kimberly Littleton Topper at least 7 days in advance of the meeting.
Contact Person:
Kimberly Littleton Topper, Center for Drug Evaluation and
Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for
express delivery, 5630 Fishers Lane, Rm. 1093) Rockville, MD 20857, 301–827–7001,
e-mail: topperk@cder.fda.gov,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572
in the Washington, DC area), code 3014512534. Please call the Information Line
for up-to-date information on this meeting.
[ Full FR Notice ]